| 초록 |
immunotoxins have been developed for targeted cancer therapy. These chimeric proteins consisting of a targeting moiety of monoclonal antibody or ligand binding to cancer cell surface receptor and potent proteins have demonstrated a powerful ability to kill cancer cells. Chemical conjugation or fusion protein methods have been explored as means to obtain immunotoxins. However, most chemical conjugation methods result in heterogeneous products, and the fused forms of immunotoxin have been reported only for antibody fragments rather than full-length ones. Here, we report a site-specifically conjugated immunotoxin composed of trastuzumab (Herceptin), targeting the HER2 receptor, and PE24 derived from Pseudomonas exotoxin A. The Trastuzumab-PE24 conjugate was characterized biochemically, and its cytotoxicity was demonstrated for the HER2-positive cells lines. We expect that the conjugation approach described in this study can be applied to prepare various antibody-protein conjugates |
